Pamela L. Kunz, MD

Following their review of recent data from the 2024 ASCO GI Cancers Symposium, the Oncology Brothers discuss their key takeaways.

Medical oncologists offer comprehensive insights on the role of circulating tumor DNA in the treatment of patients with colorectal cancer.

Clinical insights on the recent data from the NETTER-2 trial looking at Lu-177 Dotatate in patients with advanced gastroenteropancreatic neuroendocrine tumors.

Pamela L. Kunz, MD, and the Oncology Brothers provide insights on the EMERALD-1 trial looking at durvalumab and bevacizumab plus TACE in patients with unresectable, embolization-eligible hepatocellular carcinoma.

Following ASCO GI 2024, Pamela L. Kunz, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from the CheckMate 8HW study investigating nivolumab plus ipilimumab in MSI-high/mismatch repair deficient metastatic colorectal cancer.

Pamela L. Kunz, MD, discusses the most recent FDA approval of Lutathera (lutetium [Lu 177] dotatate) for the treatment of patients with gastroenteropancreatic NETs (GEP-NETs), including foregut, midgut, and hindgut tumors.

Pamela L. Kunz, MD, assistant professor of medicine (oncology), Stanford University Medical Center, discusses managing the adverse event of diarrhea in patients with carcinoid syndrome, specifically with the use of telotristat ethyl (Xermelo) during the 10th Annual NANETS Symposium.

Pamela L. Kunz, MD, discusses classifying neuroendocrine tumors (NETs) and the potential to predict response.

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the sequencing of agents for pancreatic neuroendocrine tumors (NETs).

Pamela L. Kunz, MD, assistant professor of medicine, Oncology, Stanford University Medical Center, on the use of angiogenesis inhibitors for the treatment of metastatic gastric cancer.

Pamela L. Kunz, MD, assistant professor of medicine, Oncology, Stanford University Medical Center, discusses the need to identify molecular subtypes of gastric cancer.